UPDATE: William Blair Starts Generation Bio (GBIO) at Outperform
Get Alerts GBIO Hot Sheet
Rating Summary:
4 Buy, 4 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 12 | Down: 9 | New: 10
Join SI Premium – FREE
William Blair analyst Raju Prasad initiates coverage on Generation Bio (NASDAQ: GBIO) with a Outperform rating.
The analyst comments "Exploring the clinical potential of nonviral gene therapy. While AAV gene therapy has produced impressive clinical data to date, there are some notable drawbacks to this approach. These include: 1) the size of a transgene that can be used (less than 5 kilobases of genetic cargo); 2) potential for waning of durability of effect as evidenced in BioMarin’s Roctavian long-term data in hemophilia A; 3) nonoptimal transduction efficiency, which can result in the need for higher doses and subsequently require more manufacturing lots; and 4) immunogenicity, including both preexisting neutralizing antibodies against the AAV vector and increasing the need for prophylactic steroid use with initial delivery. Generation Bio’s technology value proposition is a redosable, titratable gene therapy that allows for a larger genetic payload, tissue specificity, and a capsid-free manufacturing process, with the potential to improve on both AAV gene therapy and biologic offerings."
For an analyst ratings summary and ratings history on Generation Bio click here. For more ratings news on Generation Bio click here.
Shares of Generation Bio closed at $37.18 yesterday.
You May Also Be Interested In
- Recruit Holdings Co., Ltd (6098:JP) (RCRUY) PT Raised to JPY7,800 at Jefferies, 'emerged stronger since the last earnings season'
- HSBC Upgrades Scor SE (SCR:FP) (SCRYY) to Buy, 'cheapest way to play the positive dynamics in reinsurance'
- HSBC Downgrades Munich Re (MUV2:GR) (MURGY) to Reduce, 'dividend yield remains relatively low'
Create E-mail Alert Related Categories
Analyst Comments, New CoverageRelated Entities
William BlairSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!